Dow Jones
39.908,00 +349,89 (+0,88%) Nasdaq
16.742,39 +231,21 (+1,40%) Nikkei 225
38.385,73 +29,67 (+0,08%) EUR/USD
1,0886 +0,0065 (+0,60%) Bitcoin EUR
60.608,12 +4.049,85 (+7,16%) CMC Crypto 200
1.394,40 +126,45 (+9,94%)
Pyxis Oncology, Inc. (PYXS)
Dopo ore:
| Chiusura precedente | 4,2000 |
| Aperto | 4,2400 |
| Denaro | 4,1500 x 100 |
| Lettera | 4,2500 x 100 |
| Min-Max giorno | 4,1600 - 4,5000 |
| Intervallo di 52 settimane | 1,3500 - 6,8500 |
| Volume | |
| Media Volume | 729.134 |
| Capitalizzazione | 253,181M |
| Beta (5 anni mensile) | 1,45 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,8500 |
| Prossima data utili | 11 ago 2024 - 15 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,83 |
GlobeNewswirePyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for four different assets have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego. “We look forward to presenting a trial-in-progress poster for PYX-201, our first-in-class a
- GlobeNewswire
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced its participation in two upcoming investment conferences. On September 6, 2023, members of the Pyxis Oncology executive team will host in-person 1x1 meetings with investors during the 2023 Wells Fargo Healthcare Conference in Boston. To schedule a meeting, please reach out to your Wells Far
- GlobeNewswire
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H 2025, enabling the Company to evaluate early signs of potential clinical activity for PYX-201 and PYX-106 Guidance on development strategy, timelines and milestones for the newly acquired Phase 2 sotigalima
